Retatrutide: The Triple-Agonist Weight Loss Peptide

What is retatrutide?

Retatrutide is Eli Lilly's next-generation weight loss compound, and it may be the most effective pharmacological weight loss intervention ever studied in clinical trials. That is not hyperbole. In Phase 2 trials, the highest dose of retatrutide produced average weight loss of 24.2% of body weight at 48 weeks. For a 250-pound person, that is 60 pounds. In less than a year. From a single weekly injection.

What makes retatrutide different from the GLP-1 medications that have already transformed weight loss medicine — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — is the number of hormonal pathways it activates simultaneously. Semaglutide is a single agonist: it targets GLP-1 receptors. Tirzepatide is a dual agonist: GLP-1 plus GIP receptors. Retatrutide is a triple agonist: GLP-1, GIP, and glucagon receptors. That third mechanism — glucagon receptor activation — is the key innovation, and it adds something that previous GLP-1 medications do not: a direct increase in metabolic rate and fat burning.

Retatrutide is currently in Phase 3 clinical trials. It has not been approved by the FDA and is not available for prescription use. But the Phase 2 data has generated enormous interest in the medical and weight loss communities because the magnitude of weight loss it produces exceeds anything previously achieved with a non-surgical intervention. If the Phase 3 data confirms what Phase 2 showed, retatrutide will fundamentally change the ceiling of what pharmacological weight loss can achieve.

How retatrutide works: the triple mechanism

To understand why retatrutide is generating so much attention, you need to understand what each of its three receptor targets does and why activating all three simultaneously produces effects that exceed what any single- or dual-agonist can achieve.

GLP-1 (glucagon-like peptide-1) receptor. This is the mechanism shared with semaglutide and tirzepatide. GLP-1 receptor activation suppresses appetite by acting on hunger centers in the brain, slows gastric emptying (so you feel full longer after eating), and improves insulin secretion in response to meals. This is the foundation of the GLP-1 medication class, and it is responsible for the dramatic appetite reduction that users of Ozempic and Wegovy experience. Retatrutide includes this mechanism, providing the same appetite-suppressing benefits.

GIP (glucose-dependent insulinotropic polypeptide) receptor.This is the mechanism shared with tirzepatide. GIP receptor activation enhances insulin sensitivity, improves glucose metabolism, and appears to have direct effects on fat tissue that promote fat mobilization and reduce fat storage. The addition of GIP to GLP-1 is what made tirzepatide more effective than semaglutide in clinical trials — dual-agonism outperformed single-agonism. Retatrutide includes this mechanism as well.

Glucagon receptor.This is retatrutide's unique addition — the third agonist that neither semaglutide nor tirzepatide targets. Glucagon is traditionally thought of as the “counter-regulatory” hormone to insulin: when blood sugar drops, glucagon signals the liver to release stored glucose. But glucagon does far more than regulate blood sugar. It increases energy expenditure (metabolic rate), promotes hepatic fat oxidation (the liver burns fat for fuel), and stimulates thermogenesis (heat production from energy expenditure). In short, glucagon activation makes your body burn more calories and preferentially burn fat as the fuel source.

This is why the triple mechanism is so powerful. GLP-1 reduces how much you eat. GIP improves how your body handles the fuel you consume. Glucagon increases how much energy your body burns and shifts the fuel source toward fat. Previous GLP-1 medications worked primarily on the “input” side of the energy equation — reducing caloric intake. Retatrutide works on both sides: reducing input while simultaneously increasing output. The result is greater total weight loss and, based on early data, a higher proportion of that weight loss coming from fat rather than lean tissue.

Clinical trial results

The Phase 2 trial of retatrutide (published in the New England Journal of Medicine in 2023) enrolled 338 adults with obesity or overweight and tested multiple doses over 48 weeks. The results were striking:

• The highest dose group (12 mg) achieved average weight loss of 24.2% of body weight at 48 weeks.
• At the 8 mg dose, average weight loss was approximately 22.8%.
• Even moderate doses produced weight loss exceeding 15%, which is comparable to or better than what semaglutide achieves at its maximum approved dose.
• The weight loss curve had not plateaued at 48 weeks, suggesting that longer treatment could produce additional weight loss.
• A significant subset of participants in the highest dose group lost more than 30% of their body weight.

To put these numbers in context: bariatric surgery (Roux-en-Y gastric bypass) typically produces weight loss of 25-30% of body weight over 12-18 months. Retatrutide achieved comparable results with a weekly injection and no surgery. This is the comparison that has captured the attention of the medical community, because it suggests that pharmacological weight loss may be approaching surgical-level efficacy.

Phase 3 trials are currently underway, enrolling larger and more diverse patient populations and testing retatrutide across multiple indications including obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (formerly NAFLD). These larger trials will provide the comprehensive efficacy and safety data required for FDA approval. Eli Lilly has indicated that the Phase 3 program is on track, though specific completion and submission timelines are subject to change.

Retatrutide vs. tirzepatide vs. semaglutide

Understanding how retatrutide compares to the GLP-1 medications that are already available helps contextualize what it brings to the table. While direct head-to-head trials between retatrutide and the other compounds have not been completed, cross-trial comparisons provide a reasonable basis for comparison.

The key takeaway from this comparison is not simply that retatrutide produces more weight loss — though it does. It is that retatrutide works through a fundamentally different mechanism on the energy expenditure side. Semaglutide and tirzepatide are primarily appetite suppressants with metabolic benefits. Retatrutide is an appetite suppressant, a metabolic enhancer, and a fat-burning promoter simultaneously. This is a meaningful distinction because it suggests that retatrutide may preserve more lean mass during weight loss (since the increased energy expenditure preferentially burns fat) and may produce more durable metabolic improvements.

For a comprehensive overview of the currently available GLP-1 medications, see our Weight Loss Medications guide. If you are interested in tirzepatide specifically, our Mounjaro Online guide covers how to access it now, and our Cheapest GLP-1 guide helps navigate cost.

When will retatrutide be available?

As of early 2026, retatrutide is in Phase 3 clinical trials. The typical timeline from Phase 3 completion through FDA review and approval is 2-3 years, which places the earliest realistic FDA approval in the 2027-2028 timeframe. Several factors could accelerate or delay this timeline:

• Accelerating factors: The FDA has shown increasing willingness to prioritize obesity treatments given the scale of the epidemic. If Phase 3 data is overwhelmingly positive and consistent with Phase 2, Eli Lilly could pursue priority review or accelerated approval pathways.
• Delaying factors: Phase 3 trials enrolling larger populations may reveal safety signals not apparent in Phase 2. Manufacturing scale-up for a weekly injectable is complex. Regulatory review timelines are inherently unpredictable.

Once FDA-approved, the availability of retatrutide through compounding pharmacies will depend on patent status and FDA regulations around compounding. Currently, semaglutide is available through compounding due to ongoing shortages, and tirzepatide has a similar pathway. Whether retatrutide will be compoundable upon approval depends on patent exclusivity and supply dynamics that cannot be predicted with certainty at this point.

For people who need weight loss intervention now, the currently available options are effective and well-established. Tirzepatide, which shares two of retatrutide's three mechanisms, produces 20-25% weight loss and is available today. See our Tirzepatide Near Me guide for access options.

Legal status

Retatrutide is an investigational drug that has not received FDA approval for any indication. This means it is not legally available for prescription use in the United States. It is not a controlled substance, but it is not a legally marketable pharmaceutical either.

Some grey-market vendors and research chemical suppliers have begun offering products labeled as retatrutide. These products are unregulated, unverified, and carry significant risks. There is no quality assurance, no third-party testing requirement, and no way to verify that the product contains what the label claims at the stated potency. Purchasing and self-administering an unapproved investigational drug outside of a clinical trial is both a health risk and a legal grey area.

The responsible approach is to wait for FDA approval and access retatrutide through proper medical channels: a physician's prescription filled at a licensed pharmacy. In the meantime, currently approved GLP-1 medications offer substantial and well-characterized weight loss benefits. For a complete understanding of the legal landscape for peptides and weight loss medications, see our Are Peptides Legal? guide.

Frequently asked questions

What is retatrutide?

Retatrutide is Eli Lilly's investigational triple-agonist peptide that simultaneously targets GLP-1, GIP, and glucagon receptors. In Phase 2 trials, it produced average weight loss of 24.2% at 48 weeks at the highest dose, making it potentially the most effective weight loss compound ever studied. It is currently in Phase 3 trials and is not yet FDA-approved.

When will retatrutide be available?

Retatrutide is in Phase 3 clinical trials. Based on typical development timelines, FDA approval is estimated in the 2027-2028 timeframe. Until then, it is not legally available for prescription use. Grey-market sources should be avoided due to quality, safety, and legal concerns.

How is retatrutide different from tirzepatide?

Tirzepatide activates two receptors (GLP-1 and GIP). Retatrutide activates three (GLP-1, GIP, and glucagon). The glucagon component adds increased metabolic rate and enhanced fat oxidation, meaning the body burns more calories and preferentially burns fat. This dual action on both caloric intake and expenditure is what makes retatrutide's weight loss results exceed those of tirzepatide.

Is retatrutide safe?

Phase 2 data showed a safety profile consistent with other GLP-1 class medications. The most common side effects were gastrointestinal: nausea, diarrhea, vomiting, and constipation, generally mild to moderate and improving over time. Phase 3 trials with larger populations will provide more comprehensive safety data. No novel safety signals were identified that would differentiate retatrutide from the established GLP-1 class.

Can I get retatrutide now?

Not through legitimate channels. Retatrutide is an unapproved investigational drug available only through clinical trials. Grey-market products labeled as retatrutide are unregulated and should be avoided. For weight loss treatment available now, tirzepatide (Mounjaro/Zepbound) shares two of retatrutide's three mechanisms and produces 20-25% weight loss. See our Weight Loss Medications guide for current options.